L-687,414
Pharmaceutical compound
From Wikipedia, the free encyclopedia
L-687,414 is a glycine-site NMDA receptor antagonist or low-efficacy partial agonist (Emax ≈ 10%) which is used in scientific research.[1][2][3][4][5] It is a close analogue of HA-966.[5] The drug has been found to produce hyperlocomotion (a psychostimulant-like effect),[6][7] analgesia[4] or antinociceptive effects,[8][9] anticonvulsant effects,[2][6] and neuroprotective effects in animals.[10] In contrast to uncompetitive NMDA receptor antagonists like ketamine and phencyclidine (PCP), L-687,414 has not been associated with the development of brain vacuoles (i.e., Olney's lesions) in animals.[11]
| |
| Clinical data | |
|---|---|
| Other names | L-687414; L687414; cis-4-Methyl-HA-966 |
| Drug class | Glycine-site NMDA receptor antagonist or very weak partial agonist |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C5H10N2O2 |
| Molar mass | 130.147 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Trace amine-associated receptor 1 (TAAR1) partial and full agonists, including RO5166017, RO5203648, RO5256390, and RO5263397, have been found to reverse the hyperlocomotion induced by L-687,414 as well as by other NMDA receptor antagonists like PCP in rodents.[12][13][14][15][16] Similarly, glycine transporter 1 (GlyT1) inhibitors reverse the hyperlocomotion induced by L-687,414 in rodents.[17][7][18][19] As such, TAAR1 agonists and GlyT1 inhibitors may have antipsychotic-like properties.[12][17]
